Cascadian Therapeutics Inc (USA)  

(Public, NASDAQ:CASC)   Watch this stock  
Find more results for Nasdaq:ONTY
-0.01 (-0.79%)
Oct 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.23 - 1.27
52 week 0.82 - 3.75
Open 1.27
Vol / Avg. 171,486.00/863,007.00
Mkt cap 169.14M
P/E     -
Div/yield     -
EPS -0.54
Shares 135.31M
Beta 2.03
Inst. own 68%
Nov 3, 2016
Q3 2016 Cascadian Therapeutics Inc Earnings Release (Estimated) Add to calendar
Sep 13, 2016
Cascadian Therapeutics Inc at Rodman & Renshaw Global Investment Conference
Aug 8, 2016
Q2 2016 Cascadian Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -100.44% -32.63%
Return on average equity -119.96% -37.24%
Employees 53 -
CDP Score - -


2601 4th Ave Ste 500
SEATTLE, WA 98121-3222
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Officers and directors

Christopher S. Henney Ph.D. Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Scott D. Myers President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Julia Marie Eastland Chief Financial Officer, Vice President - Corporate Development, Secretary
Age: 49
Bio & Compensation  - Reuters
Gary W. Christianson Chief Operating Officer
Age: 60
Bio & Compensation  - Reuters
Jay Venkatesan M.D. Executive Vice President, General Manager
Age: 46
Bio & Compensation  - Reuters
Scott Peterson Ph.D. Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Director
Bio & Compensation  - Reuters
Mark Lampert Director
Bio & Compensation  - Reuters
Richard L. Jackson Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Steven P. James Independent Director
Age: 57
Bio & Compensation  - Reuters